about
DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly populatTreatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.[Colon Polypectomy - And Then?].Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer.Advantages of a multi-state approach in surgical research: how intermediate events and risk factor profile affect the prognosis of a patient with locally advanced rectal cancer.EVITA - A double-blind, vehicle controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.[ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group[Personalized tumor therapy for gastrointestinal tumors][Therapy in pancreatic cancer - and still it moves along!]Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis - Better Treatment?Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer
P50
Q30315797-9407CC5C-5984-4253-897E-F062BDCD67A4Q33996086-3E8678D4-194B-4BA0-8AC0-995A4C39DE08Q36318273-C702DE72-33E1-4292-8B70-49493DB45560Q44468954-11CEB2ED-DF84-439A-BEB9-6722F3D6E19AQ48499391-C006509E-52F2-4A1E-A460-68AD837E077AQ49883624-C3A47B58-20A3-468E-AB1C-E14193E4057EQ50089903-7E540FCC-0E05-4570-837D-98571E3BDCD0Q52593804-4DA996D1-74A5-4752-8FA9-65DDCDBEFDCAQ52650927-65E261FF-5D9A-4CDB-9FC5-B58EE1657BA8Q60925502-4119FBEA-0A32-4311-B16F-30EBE8E9DEE5Q85542005-7DDF323A-59D0-4810-AAB5-A5BE2273AAA7Q87024662-3A2F55D2-E5AA-4817-B162-CC98B1C9C5D8Q90644223-DCE61228-58F0-4681-B652-3730E029F873Q91942656-2CDE5436-175E-4D88-BA25-D1E845DF16F8
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-7654-2442
@en
name
Thomas J Ettrich
@ast
Thomas J Ettrich
@en
Thomas J Ettrich
@nl
type
label
Thomas J Ettrich
@ast
Thomas J Ettrich
@en
Thomas J Ettrich
@nl
altLabel
Thomas J. Ettrich
@en
prefLabel
Thomas J Ettrich
@ast
Thomas J Ettrich
@en
Thomas J Ettrich
@nl
P106
P214
7065151248005944270000
P31
P496
0000-0002-7654-2442
P735
P7859
viaf-7065151248005944270000